welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Researchers

Mike Gait, PhD

Researcher
Board Member
Oligonucleotide Therapeutics Society
c/o Event Innovations, Inc.
4377 Newport Avenue
San Diego, California, United States

Michael Gait obtained a PhD in 1973 in Chemistry from the University of Birmingham, UK. From 1973-75 he was Research Associate at MIT. Since 1975, he has been a staff scientist at the Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK, becoming a Medical Research Council (MRC) Programme Leader in 1994. He is a Fellow of the Royal Society of Chemistry and was elected to EMBO in 2006.

Dr. Gait was an Executive Editor of Nucleic Acids Research from 1986 – 2012 and served as senior editor for 10 years. He was President of the International Society of Nucleosides, Nucleotides and Nucleic Acid for 2009-2010 and has taken other roles in this society. He has been a board member of the Oligonucleotide Therapeutics Society practically from the very start and has helped to organize several OTS meetings, including as chair of the OTS committee for the 5th Annual meeting in Japan in 2009.

He started his career on development of solid-phase DNA and RNA synthesis and later worked on studies of ribozymes and HIV RNA-protein interactions. More recently, his group has focused on steric blocking antisense oligonucleotide analogues, initially targeting HIV RNA and more recently concentrating on PNA and PMO oligonucleotide analogues and their peptide conjugates for splicing redirection and as therapeutics for treatment of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.

 

Representative Publications:

Parallel Synthesis of Cell-Penetrating Peptide Conjugates of PMO Towards Exon Skipping Enhancement in Duchenne Muscular Dystrophy 

Peptide-Conjugated Phosphodiamidate Oligomer-Mediated Exon Skipping has Benefits for Cardiac Function in Mdx and Cmah-/-Mdx Mouse Models of Duchenne Muscular Dystrophy

Identification of Novel, Therapy-Responsive Protein Biomarkers in a Mouse Model of Duchenne Muscular Dystrophy by Aptamer-Based Serum Proteomics

In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy 

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy

rareRelated